Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 192

1.

Orbitofrontal cortex neurons as a common target for classic and glutamatergic antipsychotic drugs.

Homayoun H, Moghaddam B.

Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):18041-6. doi: 10.1073/pnas.0806669105. Epub 2008 Nov 12.

2.

Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine.

Kargieman L, Santana N, Mengod G, Celada P, Artigas F.

Proc Natl Acad Sci U S A. 2007 Sep 11;104(37):14843-8. Epub 2007 Sep 4.

3.
4.

The mechanism of action of novel antipsychotic drugs.

Meltzer HY.

Schizophr Bull. 1991;17(2):263-87. Review.

PMID:
1679253
5.

[Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].

Mechri A, Saoud M, Khiari G, d'Amato T, Dalery J, Gaha L.

Encephale. 2001 Jan-Feb;27(1):53-9. Review. French.

PMID:
11294039
7.

Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?

Marek GJ, Behl B, Bespalov AY, Gross G, Lee Y, Schoemaker H.

Mol Pharmacol. 2010 Mar;77(3):317-26. doi: 10.1124/mol.109.059865. Epub 2009 Nov 23. Review. Erratum in: Mol Pharmacol. 2010 May;77(5):884.

8.

Dynamic regulation of glutamatergic postsynaptic activity in rat prefrontal cortex by repeated administration of antipsychotic drugs.

Fumagalli F, Frasca A, Racagni G, Riva MA.

Mol Pharmacol. 2008 May;73(5):1484-90. doi: 10.1124/mol.107.043786. Epub 2008 Feb 4.

10.

Direct and indirect modulation of the N-methyl D-aspartate receptor.

Marino MJ, Conn PJ.

Curr Drug Targets CNS Neurol Disord. 2002 Feb;1(1):1-16. Review.

PMID:
12769631
11.

Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation.

Laruelle M, Frankle WG, Narendran R, Kegeles LS, Abi-Dargham A.

Clin Ther. 2005;27 Suppl A:S16-24. Review.

PMID:
16198197
12.

Antipsychotic drugs reverse the AMPA receptor-stimulated release of 5-HT in the medial prefrontal cortex.

Amargós-Bosch M, Adell A, Artigas F.

J Neurochem. 2007 Jul;102(2):550-61. Epub 2007 Mar 29.

13.
14.
15.

Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia.

Chavez-Noriega LE, Schaffhauser H, Campbell UC.

Curr Drug Targets CNS Neurol Disord. 2002 Jun;1(3):261-81. Review.

PMID:
12769619
16.

Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia.

Lindsley CW, Shipe WD, Wolkenberg SE, Theberge CR, Williams DL Jr, Sur C, Kinney GG.

Curr Top Med Chem. 2006;6(8):771-85. Review.

PMID:
16719816
17.
18.
19.

F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum.

Bruins Slot LA, Lestienne F, Grevoz-Barret C, Newman-Tancredi A, Cussac D.

Eur J Pharmacol. 2009 Oct 12;620(1-3):27-35. doi: 10.1016/j.ejphar.2009.08.019. Epub 2009 Aug 18.

PMID:
19695244
20.

Antipsychotic drug effects on glutamatergic activity.

Lidsky TI, Yablonsky-Alter E, Zuck LG, Banerjee SP.

Brain Res. 1997 Aug 1;764(1-2):46-52.

PMID:
9295192

Supplemental Content

Support Center